The pre-menopausal status has been associated with decreased endoxifen plasma concentrations by 135% compared to post-menopausal status in tamoxifen-treated breast cancer patients phenotyped as NMs for CYP2D6 and with CYP3A activity [111]. The gene discussed is CYP3A4; the disease is breast carcinoma.